表紙
市場調査レポート

ポイントオブケア (POC) 診断の世界市場予測 2021年:グルコースモニタリング・心血管代謝モニタリング・感染症検査キット・心臓マーカー・腫瘍マーカー

Point-of-Care Diagnostics Market by Products (Glucose, Cardiometabolic Monitoring, & Infectious Disease Testing Kits, Cardiac & Tumor Markers), End Users (Home, Hospitals, Ambulatory Care), Over-the-Counter & Prescription Based - Global Forecast to 2021

発行 MarketsandMarkets 商品コード 298728
出版日 ページ情報 英文 222 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
ポイントオブケア (POC) 診断の世界市場予測 2021年:グルコースモニタリング・心血管代謝モニタリング・感染症検査キット・心臓マーカー・腫瘍マーカー Point-of-Care Diagnostics Market by Products (Glucose, Cardiometabolic Monitoring, & Infectious Disease Testing Kits, Cardiac & Tumor Markers), End Users (Home, Hospitals, Ambulatory Care), Over-the-Counter & Prescription Based - Global Forecast to 2021
出版日: 2016年07月07日 ページ情報: 英文 222 Pages
概要

ポイントオブケア (POC) 診断の市場規模は、2016年から2021年にかけて9.8%のCAGR (年間複合成長率) で推移し、2021年までに369億6,000万米ドルに達すると予測されています。全体的なPOC診断市場の成長は、世界的な生活習慣病・感染症のまん延および在宅医療に向かう傾向の高まりといった要因によって促進されています。

当レポートでは、世界のポイントオブケア (POC) 診断/検査市場について調査し、市場の概要、最近の主要動向、製品区分・エンドユーザー・処方区分・地域/主要国別の市場規模の推移と予測、市場影響因子、課題などの分析、および主要企業のプロファイルなどを詳細に渡ってまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • ポイントオブケア診断市場の概要
  • 地域分析:POC診断市場の成長率、製品別
  • 地域分析:POC診断市場の規模、処方法別
  • POC診断市場:エンドユーザー・地域別

第5章 ポイントオブケア (POC) 診断の世界市場:概要

  • イントロダクション
  • 市場区分
  • 市場ダイナミクス
    • 市場成長促進要因
    • 市場成長阻害要因
    • 市場機会
    • 市場課題
    • 緊急の問題

第6章 ポイントオブケア (POC) 診断業界のトレンド

  • イントロダクション
  • 業界のトレンド
    • POC検査機器の標準化
    • 小規模企業の買収
    • マイクロ流体ベースのPOCデバイスに対する注目度の高まり
  • 価格設定とコストについての分析
  • ポーターのファイブフォース分析
  • 戦略的ベンチマーキング

第7章 ポイントオブケア (POC) 診断の世界市場:製品別

  • イントロダクション
  • グルコースモニタリングキット市場
  • 心血管代謝モニタリングキット
    • 心筋マーカー
    • 血液ガス/電解質検査キット
    • HbA1 (グリコヘモグロビン) 検査キット
    • 脂質検査キット
  • 感染症検査キット
    • インフルエンザ検査キット
    • HIV検査キット
    • C型肝炎検査キット
    • 性感染症 (STDS) 検査キット
    • 熱帯病検査キット
    • 医療関連感染検査キット
    • 呼吸器感染検査キットの市場
    • その他の感染症検査キット
  • 血液凝固モニタリングキット
    • プロトロンビン時間 (PT/INR) 検査キット
    • 活性凝固時間 (ACT/APTT) 検査キット
  • 妊娠および受胎能検査キット
    • 妊娠検査キット
    • 受胎能検査キット
  • 腫瘍/がんマーカー
  • 尿検査キット
  • コレステロール検査ストリップ
  • 血液学的検査キット
  • 薬物乱用検査キット
  • 便中潜血検査キット
  • 他の検査キット

第8章 ポイントオブケア (POC) 診断の世界市場:処方法別

  • イントロダクション
  • 処方箋が必要な検査キット
  • OTC検査キットの市場

第9章 ポイントオブケア (POC) 診断の世界市場:エンドユーザー別

  • イントロダクション
  • 専門診断センター
  • 研究ラボ
  • 在宅医療
  • その他

第10章 ポイントオブケア (POC) 診断の世界市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • 他の国々
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 他の国々
  • その他 (ROW)

第11章 競合環境

  • 概要
  • 市場シェア分析
  • 血中グルコース監視キットの市場シェア分析
  • 競合状況・動向

第12章 企業プロファイル

  • イントロダクション
  • ROCHE DIAGNOSTICS LIMITED (F. HOFFMANN-LA ROCHE LTD. 子会社)
  • ABBOTT LABORATORIES, INC.
  • SIEMENS AG
  • ALERE INC.
  • JOHNSON & JOHNSON
  • INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
  • NOVA BIOMEDICAL
  • BECKMAN COULTER, INC. (DANAHER CORPORATION 子会社)
  • BECTON, DICKINSON AND COMPANY
  • PTS DIAGNOSTICS

第13章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MD 2702

The point-of-care diagnostics market is expected to reach USD 36.96 billion by 2021, at a CAGR of 9.8% from 2016 to 2021.

The growth of the overall point-of-care diagnostics market is driven by factors such as prevalence of lifestyle and infectious diseases and the increasing inclination towards home healthcare across the globe. In addition, healthcare decentralization, miniaturization of POC testing devices, increasing number of conferences and events, and POC tests with multiplexing capabilities are offering new growth opportunities for players in the point-of-care diagnostics market. On the other hand, stringent and time-consuming regulatory policies and pricing pressure owing to reimbursement cuts and budget constraints are the key challenges faced by the market players involved in the POC diagnostics market.

In this report, the point-of-care diagnostics market has been segmented on the basis of product (covering glucose monitoring testing kits, cardiometabolic testing kits, infectious disease testing kits, and urinalysis testing kits, among others), mode of prescription (OTC and prescription-based testing kits), end-users (professional diagnostic centers, home care, and research laboratories), and region (North America, Europe, APAC, and RoW). On the basis of products, the glucose monitoring kits segment is estimated to account for the largest share of the point-of-care diagnostics market in 2016. Rising diagnosis of diabetes, ongoing technological advancements in devices used for self-monitoring blood glucose level, and growing patient awareness towards POC testing is driving the growth of this segment across the globe.

Geographically, North America (comprising the U.S. and Canada) is expected to command the largest share of the point-of-care diagnostics market in 2016, followed by Europe. A number of factors such as growing prevalence of lifestyle diseases, increasing number of product approvals, and rising government initiatives are contributing to the growth of the North American point-of-care diagnostics market. However, rising pricing pressure and slow approval of multi-analyte POC products is limiting the growth of point-of-care diagnostics market in North America.

The point-of-care diagnostics market consists of a large number of big, medium, and small-sized companies. As of 2015, the point-of-care diagnostics market was dominated by Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), and Alere, Inc. (U.S.). New product launches and product approvals; partnerships, agreements, and collaborations; acquisitions; and expansions were the major strategies adopted by most of the market players between 2013 and 2016 to achieve growth in the point-of-care diagnostics market.

Reasons to Buy the Report:

From an insight perspective, this research report focuses on various levels of analysis-market share analysis of top players and company profiles, which together comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the global point-of-care diagnostics market; and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned four strategies (market penetration, product development/innovation, market development, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on point-of-care diagnostic devices offered by the top 10 players in the point-of-care diagnostics market. The report analyzes the point-of-care diagnostic devices market by product and region
  • Product Development/Innovation: Detailed insights on current and upcoming technologies, research and development activities, product enhancements, and new product launches in the point-of-care diagnostics market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various point-of-care diagnostics devices across four geographies
  • Competitive Assessment: Assessment of market shares, strategies, and products of leading players in the point-of-care diagnostics market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
  • 1.4. MARKETS COVERED
    • 1.4.1. YEARS CONSIDERED FOR THE STUDY
  • 1.5. CURRENCY
  • 1.6. LIMITATIONS
  • 1.7. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION METHODOLOGY
    • 2.2.1. BOTTOM-UP APPROACH
    • 2.2.2. TOP-DOWN APPROACH
  • 2.3. RESEARCH DESIGN
  • 2.4. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: POINT-OF-CARE DIAGNOSTICS MARKET GROWTH RATE, BY PRODUCT (2016-2021)
  • 4.3. GEOGRAPHIC ANALYSIS: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY MODE OF PRESCRIPTION, 2016 VS. 2021
  • 4.4. POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER AND REGION, 2016(USD MILLION)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. High prevalence of infectious diseases in developing countries
      • 5.3.1.2. Increasing incidence of lifestyle diseases
      • 5.3.1.3. Rising usage of home-based POC devices
      • 5.3.1.4. Growing government support
      • 5.3.1.5. Private investments and venture capital activities
      • 5.3.1.6. Technological advancements and new product launches
      • 5.3.1.7. Growing number of regulatory approvals for novel immunoassay techniques
      • 5.3.1.8. Shortage of skilled laboratory technicians increasing preference of POC testing
      • 5.3.1.9. Rising number of CLIA-waived POC tests
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Product recalls
      • 5.3.2.2. Pricing pressures owing to reimbursement cuts and budget constraints hampering profits
      • 5.3.2.3. Stringent and time-consuming regulatory policies are significantly increasing gestation period for product launches
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Emerging markets (India, China, and Brazil) to pave new growth avenues
      • 5.3.3.2. Healthcare decentralization-converting lab tests to POC tests
      • 5.3.3.3. Increasing number of conferences and events
      • 5.3.3.4. Miniaturization of POC testing devices
      • 5.3.3.5. POC tests with multiplexing capabilities
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Lack of alignment with definitive central lab methods
      • 5.3.4.2. Disadvantages of POC testing over central lab methods
      • 5.3.4.3. Inadequate knowledge about use of POC devices in professional settings
      • 5.3.4.4. Reluctance towards changing existing treatment practices
    • 5.3.5. BURNING ISSUES
      • 5.3.5.1. Unfavorable reimbursement limiting the adoption of POC tests
      • 5.3.5.2. High cost of devices-a prime concern
      • 5.3.5.3. Negative public perception related to POC tests

6. INDUSTRY TRENDS

  • 6.1. INTRODUCTION
  • 6.2. INDUSTRY TRENDS
    • 6.2.1. STANDARDIZATION OF POC TESTING DEVICES
    • 6.2.2. ACQUISITION OF SMALL PLAYERS
    • 6.2.3. GROWING FOCUS ON MICROFLUIDICS-BASED POC DEVICES
      • 6.2.3.1. Microfluidics-based LOC devices will bring laboratory testing to the patient's fingertips
      • 6.2.3.2. Evolution of paper-based microfluidic POC diagnostic devices
  • 6.3. PRICING AND COST ANALYSIS
  • 6.4. PORTER'S FIVE FORCES ANALYSIS
    • 6.4.1. THREAT FROM NEW ENTRANTS
    • 6.4.2. THREAT OF SUBSTITUTES
    • 6.4.3. BARGAINING POWER OF SUPPLIERS
    • 6.4.4. BARGAINING POWER OF BUYERS
    • 6.4.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.5. STRATEGIC BENCHMARKING
    • 6.5.1. TECHNOLOGY INTEGRATION & NEW PRODUCT LAUNCHES
    • 6.5.2. INCORPORATION OF WIRELESS TECHNOLOGY IN POC DEVICES

7. POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT

  • 7.1. INTRODUCTION
  • 7.2. GLUCOSE MONITORING KITS
  • 7.3. CARDIOMETABOLIC MONITORING KITS
    • 7.3.1. CARDIAC MARKERS
    • 7.3.2. BLOOD GAS/ELECTROLYTES TESTING KITS
    • 7.3.3. HBA1C TESTING KITS
    • 7.3.4. LIPID TESTING KITS
  • 7.4. INFECTIOUS DISEASE TESTING KITS
    • 7.4.1. INFLUENZA TESTING KITS
    • 7.4.2. HIV TESTING KITS
    • 7.4.3. HEPATITIS C TESTING KITS
    • 7.4.4. SEXUALLY TRANSMITTED DISEASES (STDS) TESTING KITS
    • 7.4.5. TROPICAL DISEASES TESTING KITS
    • 7.4.6. HEALTHCARE-ASSOCIATED INFECTION TESTING KITS
    • 7.4.7. RESPIRATORY INFECTIONS TESTING KITS
    • 7.4.8. OTHER INFECTIOUS DISEASE TESTING KITS
  • 7.5. COAGULATION MONITORING KITS
    • 7.5.1. PT/INR TESTING KITS
    • 7.5.2. ACTIVATED CLOTTING TIME (ACT/APTT) TESTING KITS
  • 7.6. PREGNANCY AND FERTILITY TESTING KITS
    • 7.6.1. PREGNANCY TESTING KITS
    • 7.6.2. FERTILITY TESTING KITS
  • 7.7. TUMOR/CANCER MARKERS
  • 7.8. URINALYSIS TESTING KITS
  • 7.9. CHOLESTEROL TEST STRIPS
  • 7.10. HEMATOLOGY TESTING KITS
  • 7.11. DRUGS-OF-ABUSE TESTING KITS
  • 7.12. FECAL OCCULT TESTING KITS
  • 7.13. OTHER POC TESTING KITS

8. POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE

  • 8.1. INTRODUCTION
  • 8.2. PRESCRIPTION-BASED TESTING KITS
  • 8.3. OTC TESTING KITS MARKET

9. POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PROFESSIONAL DIAGNOSTIC CENTERS
    • 9.2.1. HOSPITALS/CRITICAL CARE SETTINGS
    • 9.2.2. OUTPATIENT HEALTHCARE SETTINGS
    • 9.2.3. AMBULATORY CARE SETTINGS
  • 9.3. RESEARCH LABORATORIES
  • 9.4. HOME CARE
  • 9.5. OTHERS

10. POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
      • 10.2.1.1. Growing prevalence of lifestyle diseases and rising geriatric population
      • 10.2.1.2. Increasing government and venture capital funding
      • 10.2.1.3. Growing number of product approvals using CLIA waiver
      • 10.2.1.4. NIH support for the development of POC testing devices
      • 10.2.1.5. Slow inflow of multi-analyte POC devices
    • 10.2.2. CANADA
      • 10.2.2.1. Expanding patient population base
      • 10.2.2.2. Increasing focus of players on the Canadian market
      • 10.2.2.3. Increasing government initiatives
      • 10.2.2.4. Lack of reimbursement and awareness
  • 10.3. EUROPE
    • 10.3.1. GERMANY
      • 10.3.1.1. Increasing number of conferences
      • 10.3.1.2. Ongoing development of novel products
      • 10.3.1.3. Rising incidence of diabetes and cancer in Germany
      • 10.3.1.4. Low reimbursement affecting market growth in the country
    • 10.3.2. FRANCE
      • 10.3.2.1. Increasing reimbursement for point-of-care tests
      • 10.3.2.2. High prevalence of diabetes in France
    • 10.3.3. U.K.
      • 10.3.3.1. Growing number of new product launches
      • 10.3.3.2. Increasing government support for POCT devices
      • 10.3.3.3. Budget constraints hampering market growth
    • 10.3.4. REST OF EUROPE (ROE)
  • 10.4. ASIA-PACIFIC
    • 10.4.1. JAPAN
      • 10.4.1.1. Growing initiatives by market players
      • 10.4.1.2. Increasing demand for rapid flu tests in Japan
      • 10.4.1.3. Centralized healthcare delivery system
    • 10.4.2. CHINA
      • 10.4.2.1. Increasing partnerships and joint ventures fueling market growth
      • 10.4.2.2. Increasing support from government and private companies
      • 10.4.2.3. Poor reimbursement and time-consuming product registration procedure
    • 10.4.3. INDIA
      • 10.4.3.1. Increasing prevalence of target diseases
      • 10.4.3.2. Growing government initiatives
      • 10.4.3.3. Conferences
      • 10.4.3.4. Lack of reimbursement and insurance coverage hampering market growth
    • 10.4.4. REST OF ASIA-PACIFIC
  • 10.5. REST OF THE WORLD (ROW)
      • 10.5.1.1. Increasing patient population in Africa
      • 10.5.1.2. Huge patient base for respiratory diseases
      • 10.5.1.3. Growing initiatives by market players

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
  • 11.3. COMPETITIVE SITUATION AND TRENDS
    • 11.3.1. NEW PRODUCT LAUNCHES,PRODUCT ENHANCEMENTS, AND PRODUCT APPROVALS
    • 11.3.2. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 11.3.3. PRODUCT SHOWCASE AND PRODUCT RECALL
    • 11.3.4. ACQUISITIONS
    • 11.3.5. OTHER STRATEGIES

12. COMPANY PROFILES *(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 12.1. INTRODUCTION
  • 12.2. ROCHE DIAGNOSTICS LIMITED (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.)
  • 12.3. ABBOTT LABORATORIES, INC.
  • 12.4. SIEMENS AG
  • 12.5. ALERE INC.
  • 12.6. JOHNSON & JOHNSON
  • 12.7. INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
  • 12.8. NOVA BIOMEDICAL
  • 12.9. BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER CORPORATION)
  • 12.10. BECTON, DICKINSON AND COMPANY
  • 12.11. PTS DIAGNOSTICS

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. DISCUSSION GUIDE
  • 13.2. OTHER DEVELOPMENTS
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 2: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 3: GLUCOSE MONITORING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: CARDIOMETABOLIC MONITORING KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 5: CARDIOMETABOLIC MONITORING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 6: CARDIAC MARKERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 7: BLOOD GAS/ELECTROLYTES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: HBA1C TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: LIPID TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 10: INFECTIOUS DISEASE TESTING KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 11: INFECTIOUS DISEASE TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: INFLUENZA TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: HIV TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: HEPATITIS C TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 15: STD TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: TROPICAL DISEASES TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: HEALTHCARE-ASSOCIATED INFECTION TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: RESPIRATORY INFECTIONS TESTING KITS MARKET SIZE, BY REGION, 2014--2021 (USD MILLION)
  • TABLE 19: OTHER INFECTIOUS DISEASE TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: COAGULATION MONITORING KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 21: COAGULATION MONITORING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: PT/INR TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: ACT/APTT TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: PREGNANCY AND FERTILITY TESTING KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 25: PREGNANCY AND FERTILITY TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 26: PREGNANCY TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: FERTILITY TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 28: TUMOR/CANCER MARKERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 29: URINALYSIS TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 30: CHOLESTEROL TEST STRIPS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 31: HEMATOLOGY TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 32: DRUGS-OF-ABUSE TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 33: FECAL OCCULT TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 34: OTHER POC TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 35: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 36: PRESCRIPTION-BASED TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 37: OTC TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 38: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 39: PROFESSIONAL DIAGNOSTIC CENTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 40: PROFESSIONAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 41: RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 42: HOME CARE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 43: OTHER END USERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 44: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 45: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 46: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 47: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 48: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 49: U.S.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 50: U.S.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 51: U.S.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 52: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 53: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 54: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 55: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 56: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 57: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 58: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 59: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 60: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 61: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 62: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 63: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 64: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 65: U.K.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 66: U.K.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 67: U.K.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 68: ROE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 69: ROE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 70: ROE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 71: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 72: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 73: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 74: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 75: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 76: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 77: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 78: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 79: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 80: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 81: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 82: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 83: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 84: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 85: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 86: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 87: ROW: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 88: ROW: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 89: ROW: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 90: TOP 5 NEW PRODUCT LAUNCHES, PRODUCT ENHANCEMENTS, AND PRODUCT APPROVALS, 2015 & 2016
  • TABLE 91: TOP 5 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2015 & 2016
  • TABLE 92: PRODUCT SHOWCASE AND PRODUCT RECALL, 2013 & 2014
  • TABLE 93: ACQUISITIONS, 2013 & 2014
  • TABLE 94: TOP 5 OTHER STRATEGIES, 2013-2015

LIST OF FIGURES

  • FIGURE 1: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: DATA TRIANGULATION METHODOLOGY
  • FIGURE 4: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2016 (USD MILLION)
  • FIGURE 5: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2016 VS. 2021
  • FIGURE 6: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2016 VS. 2021
  • FIGURE 7: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2016-2021 (USD MILLION)
  • FIGURE 8: INCREASING PREVALENCE OF INFECTIOUS AND LIFESTYLE DISEASES IS DRIVING GROWTH IN THE POINT-OF-CARE DIAGNOSTICS MARKET
  • FIGURE 9: THE INFECTIOUS DISEASE TESTING KITS SEGMENT IN THE ASIA-PACIFIC REGION TO OFFER LUCRATIVE GROWTH OPPORTUNITIES FOR MARKET PLAYERS
  • FIGURE 10: PRESCRIPTION-BASED TESTING KITS SEGMENT TO DOMINATE THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2016
  • FIGURE 11: PROFESSIONAL DIAGNOSTIC CENTERS TO DOMINATE THE GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET IN 2016
  • FIGURE 12: POC DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 13: POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 14: GLOBAL NUMBER HIV PATIENTS, 2014 (MILLION)
  • FIGURE 15: INCIDENCE RATE OF TB IN DEVELOPING NATIONS, 2014
  • FIGURE 16: ESTIMATED NUMBER OF DIABETIC PATIENTS, BY REGION, 2015 VS. 2040
  • FIGURE 17: HEALTHCARE DECENTRALIZATION ACROSS PROMINENT COUNTRIES, 2013
  • FIGURE 18: PRICING TREND (2013-2018): TWOFOLD DECLINE EXPECTED IN THE PRICE OF POC DEVICES IN APAC AS COMPARED TO NORTH AMERICA
  • FIGURE 19: PORTER'S FIVE FORCES ANALYSIS (2016): LOW CAPITAL REQUIREMENT INCREASING COMPETITION IN THE INDUSTRY
  • FIGURE 20: STRATEGIC BENCHMARKING: ROCHE AND ABBOTT LARGELY FOCUS ON TECHNOLOGICAL INTEGRATION AND PRODUCT ENHANCEMENT
  • FIGURE 21: STRATEGIC BENCHMARKING: ALERE AND ABBOTT LARGELY ADOPT STRATEGIES FOR PRODUCT ENHANCEMENT
  • FIGURE 22: THE INFECTIOUS DISEASE TESTING KITS SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 23: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET IN 2016
  • FIGURE 24: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL GLUCOSE MONITORING KITS MARKET IN 2016
  • FIGURE 25: THE BLOOD GAS/ELECTROLYTES SEGMENT TO WITNESS HIGHEST GROWTH IN THE GLOBAL CARDIOMETABOLIC MONITORING KITS MARKET DURING THE FORECAST PERIOD
  • FIGURE 26: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE GLOBAL CARDIOMETABOLIC MONITORING KITS MARKET DURING THE FORECAST PERIOD
  • FIGURE 27: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLOOD GAS/ELECTROLYTES MARKET IN 2016
  • FIGURE 28: HEPATITIS C TESTING KITS SEGMENT TO WITNESS HIGHEST GROWTH IN THE GLOBAL INFECTIOUS DISEASE TESTING KITS MARKET DURING THE FORECAST PERIOD
  • FIGURE 29: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL INFECTIOUS DISEASES TESTING KITS MARKET IN 2016
  • FIGURE 30: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE GLOBAL HEPATITIS C TESTING KITS MARKET IN 2016
  • FIGURE 31: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE GLOBAL HAI TESTING KITS MARKET IN 2016
  • FIGURE 32: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PREGNANCY & FERTILITY TESTING KITS MARKET IN 2016
  • FIGURE 33: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL HEMATOLOGY TESTING KITS MARKET IN 2016
  • FIGURE 34: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE GLOBAL FECAL OCCULT TESTING KITS MARKET DURING THE FORECAST PERIOD
  • FIGURE 35: OTC TESTING KITS SEGMENT TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 36: NORTH AMERICA TO DOMINATE THE PRESCRIPTION-BASED TESTING KITS MARKET IN 2016
  • FIGURE 37: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE OTC TESTING KITS SEGMENT
  • FIGURE 38: BROAD END-USER BASE FOR POINT-OF-CARE TESTING KITS
  • FIGURE 39: HOME CARE END-USER SEGMENT TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 40: NORTH AMERICA TO DOMINATE THE PROFESSIONAL DIAGNOSTIC CENTERS MARKET IN 2016
  • FIGURE 41: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 42: POINT-OF-CARE DIAGNOSTICS MARKET: GROWTH FORECAST, BY REGION (2016-2021)
  • FIGURE 43: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 44: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 45: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 46: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 47: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES, PRODUCT ENHANCEMENTS, AND PRODUCT APPROVALS-KEY GROWTH STRATEGY ADOPTED BETWEEN 2013 & 2016
  • FIGURE 48: GEOGRAPHIC REVENUE SNAPSHOT (2015)
  • FIGURE 49: ROCHE DIAGNOSTICS LIMITED: COMPANY SNAPSHOT
  • FIGURE 50: ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 51: SIEMENS AG: COMPANY SNAPSHOT
  • FIGURE 52: ALERE INC.: COMPANY SNAPSHOT
  • FIGURE 53: JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 54: DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 55: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
Back to Top